Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/IDO1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/IDO1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/IDO1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/IDO1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/IDO1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00229009 | Cervix | CC | electron transport chain | 53/2311 | 175/18723 | 2.23e-10 | 3.43e-08 | 53 |
GO:00060919 | Cervix | CC | generation of precursor metabolites and energy | 105/2311 | 490/18723 | 7.40e-09 | 6.61e-07 | 105 |
GO:00075654 | Cervix | CC | female pregnancy | 43/2311 | 193/18723 | 7.62e-05 | 1.04e-03 | 43 |
GO:00467008 | Cervix | CC | heterocycle catabolic process | 80/2311 | 445/18723 | 3.23e-04 | 3.42e-03 | 80 |
GO:00447064 | Cervix | CC | multi-multicellular organism process | 45/2311 | 220/18723 | 4.14e-04 | 4.21e-03 | 45 |
GO:00442709 | Cervix | CC | cellular nitrogen compound catabolic process | 79/2311 | 451/18723 | 7.80e-04 | 6.91e-03 | 79 |
GO:00194398 | Cervix | CC | aromatic compound catabolic process | 79/2311 | 467/18723 | 2.14e-03 | 1.54e-02 | 79 |
GO:19013618 | Cervix | CC | organic cyclic compound catabolic process | 80/2311 | 495/18723 | 6.77e-03 | 3.72e-02 | 80 |
GO:000911710 | Cervix | CC | nucleotide metabolic process | 79/2311 | 489/18723 | 7.16e-03 | 3.85e-02 | 79 |
GO:000756512 | Cervix | HSIL_HPV | female pregnancy | 26/737 | 193/18723 | 4.32e-08 | 3.41e-06 | 26 |
GO:004470611 | Cervix | HSIL_HPV | multi-multicellular organism process | 27/737 | 220/18723 | 1.69e-07 | 1.03e-05 | 27 |
GO:002290014 | Cervix | HSIL_HPV | electron transport chain | 18/737 | 175/18723 | 1.93e-04 | 3.56e-03 | 18 |
GO:000609114 | Cervix | HSIL_HPV | generation of precursor metabolites and energy | 32/737 | 490/18723 | 3.69e-03 | 3.27e-02 | 32 |
GO:000609110 | Endometrium | AEH | generation of precursor metabolites and energy | 121/2100 | 490/18723 | 1.65e-17 | 8.23e-15 | 121 |
GO:002290010 | Endometrium | AEH | electron transport chain | 60/2100 | 175/18723 | 4.37e-16 | 1.75e-13 | 60 |
GO:00075655 | Endometrium | AEH | female pregnancy | 43/2100 | 193/18723 | 7.52e-06 | 1.80e-04 | 43 |
GO:004427010 | Endometrium | AEH | cellular nitrogen compound catabolic process | 80/2100 | 451/18723 | 2.09e-05 | 4.13e-04 | 80 |
GO:00467009 | Endometrium | AEH | heterocycle catabolic process | 79/2100 | 445/18723 | 2.27e-05 | 4.35e-04 | 79 |
GO:00447065 | Endometrium | AEH | multi-multicellular organism process | 45/2100 | 220/18723 | 4.55e-05 | 7.61e-04 | 45 |
GO:00194399 | Endometrium | AEH | aromatic compound catabolic process | 80/2100 | 467/18723 | 7.21e-05 | 1.10e-03 | 80 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IDO1 | SNV | Missense_Mutation | novel | c.367N>G | p.Ile123Val | p.I123V | P14902 | protein_coding | deleterious(0.04) | possibly_damaging(0.55) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
IDO1 | SNV | Missense_Mutation | novel | c.127G>T | p.Ala43Ser | p.A43S | P14902 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
IDO1 | SNV | Missense_Mutation | novel | c.451T>G | p.Leu151Val | p.L151V | P14902 | protein_coding | deleterious(0.04) | probably_damaging(0.937) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
IDO1 | SNV | Missense_Mutation | novel | c.643C>A | p.His215Asn | p.H215N | P14902 | protein_coding | tolerated(0.23) | benign(0.021) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
IDO1 | SNV | Missense_Mutation | | c.678T>G | p.Phe226Leu | p.F226L | P14902 | protein_coding | deleterious(0) | probably_damaging(0.944) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
IDO1 | SNV | Missense_Mutation | novel | c.4N>T | p.Ala2Ser | p.A2S | P14902 | protein_coding | tolerated_low_confidence(0.06) | benign(0.086) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IDO1 | SNV | Missense_Mutation | rs370075063 | c.463N>A | p.Arg155Ser | p.R155S | P14902 | protein_coding | deleterious(0) | benign(0.237) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IDO1 | SNV | Missense_Mutation | novel | c.259A>C | p.Thr87Pro | p.T87P | P14902 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
IDO1 | SNV | Missense_Mutation | rs751350971 | c.596C>T | p.Ala199Val | p.A199V | P14902 | protein_coding | deleterious(0) | probably_damaging(0.94) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
IDO1 | insertion | Frame_Shift_Ins | novel | c.577_578insG | p.Asp194GlyfsTer57 | p.D194Gfs*57 | P14902 | protein_coding | | | TCGA-EY-A1GK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3620 | IDO1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | Benzimidazole and imadazopyridine carboximidamide compound 1 | | |
3620 | IDO1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | Cyclic hydroxamate derivative 1 | | |
3620 | IDO1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | PHENYLHYDRAZINE | PHENYLHYDRAZINE | 24262887 |
3620 | IDO1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | 363894234 | | |
3620 | IDO1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | Biphenyl derivative 2 | | |
3620 | IDO1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | PMID29473428-Compound-14 | | |
3620 | IDO1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | 2,3-diamino-benzo[b]thiophene derivative 8 | | |
3620 | IDO1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | NLG8189 | | |
3620 | IDO1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | PMID29473428-Compound-53 | | |
3620 | IDO1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | 249565907 | | |